Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer

Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies rarely report comparisons with CTC counts and biopsy AR-V7 protein expression. To determine th...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2019-11, Vol.76 (5), p.676-685
Main Authors: Sharp, Adam, Welti, Jon C., Lambros, Maryou B.K., Dolling, David, Rodrigues, Daniel Nava, Pope, Lorna, Aversa, Caterina, Figueiredo, Ines, Fraser, Jennifer, Ahmad, Zai, Lu, Changxue, Rescigno, Pasquale, Kolinsky, Michael, Bertan, Claudia, Seed, George, Riisnaes, Ruth, Miranda, Susana, Crespo, Mateus, Pereira, Rita, Ferreira, Ana, Fowler, Gemma, Ebbs, Berni, Flohr, Penny, Neeb, Antje, Bianchini, Diletta, Petremolo, Antonella, Sumanasuriya, Semini, Paschalis, Alec, Mateo, Joaquin, Tunariu, Nina, Yuan, Wei, Carreira, Suzanne, Plymate, Stephen R., Luo, Jun, de Bono, Johann S.
Format: Article
Language:English
Subjects:
Alternative Splicing
Androgen receptor
Androgen receptor splice variant-7
Biomarker
Biopsy - methods
Cell Count - methods
Drug Resistance, Neoplasm
Genetic Techniques
Humans
Liquid biopsy
Male
Metastatic castration-resistant prostate cancer
Middle Aged
Neoplasm Metastasis - diagnosis
Neoplasm Metastasis - genetics
Neoplasm Staging
Neoplastic Cells, Circulating - metabolism
Neoplastic Cells, Circulating - pathology
Prognosis
Prognostic
Prostatic Neoplasms, Castration-Resistant - genetics
Prostatic Neoplasms, Castration-Resistant - pathology
Protein Isoforms - genetics
Receptors, Androgen - genetics
Reproducibility of Results
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies rarely report comparisons with CTC counts and biopsy AR-V7 protein expression. To determine the reproducibility of AdnaTest CTC AR-V7 testing, and associations with clinical characteristics, CellSearch CTC counts, tumour biopsy AR-V7 protein expression and overall survival (OS). CTC AR-V7 status was determined for 227 peripheral blood samples, from 181 mCRPC patients with CTC counts (202 samples; 136 patients) and matched mCRPC biopsies (65 samples; 58 patients). CTC AR-V7 status was associated with clinical characteristics, CTC counts, and tissue biopsy AR-V7 protein expression. The association of CTC AR-V7 status and other baseline variables with OS was determined. Of the samples, 35% were CTC+/AR-V7+. CTC+/AR-V7+ samples had higher CellSearch CTC counts (median CTC; interquartile range [IQR]: 60, 19–184 vs 9, 2–64; Mann-Whitney test p
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2019.04.006